Product Description
Transdermal contraceptive delivery system (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02158572)
Mechanisms of Action: PR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Agile
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Agile Therapeutics' Twirla® (AG200-15) has a PDUFA goal date of February 16, 2020 for FDA approval submission.
- The FDA's PDUFA goal date for Agile Therapeutics' Twirla (AG200-15) contraceptive patch is November 16, 2019.
Highest Development Phases
Phase 3: Contraception
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2011-000087-95 |
2011-000087-95 | P3 |
Completed |
Contraception |
2025-01-30 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/01/2023 |
News Article |
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation |
|
05/20/2021 |
News Article |
Transdermal Drug Delivery Market Report 2020-2030 |
|
05/15/2020 |
News Article |
Transdermal Drug Delivery Industry Assessment 2018-2028 Featuring Profiles of 100 Companies along with 105 Collaborations - ResearchAndMarkets.com |
|
05/15/2020 |
News Article |
Worldwide Transdermal Drug Delivery Markets, Therapeutics, Technologies and Players - Forecast to 2028 |